DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uetrecht, J. P.
Right arrow Articles by Oates, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uetrecht, J. P.
Right arrow Articles by Oates, J. A.

Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes

JP Uetrecht, BJ Sweetman, RL Woosley and JA Oates

We have previously demonstrated that procainamide is oxidized to a reactive metabolite. We speculated that this reactive metabolite might be a hydroxylamine and further that it might be responsible for the syndrome of procainamide-induced lupus. We now report that procainamide is metabolized to a hydroxylamine by rat and human hepatic microsomes. The extent of this metabolic oxidation was quantitated by HPLC after conversion of the hydroxylamine to the more stable nitro derivative of procainamide. Formation of the hydroxylamine required NADPH, active microsomes, and oxygen and was inhibited by carbon monoxide, SKF 525-A, and cimetidine. Formation of the hydroxylamine was also studied as a function of time, microsomal protein concentration, and procainamide concentration.

Volume 12, Issue 1, pp. 77-81, 01/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
J. M. Hutzler, M. J. Hauer, and T. S. Tracy
Dapsone Activation of CYP2C9-Mediated Metabolism: Evidence for Activation of Multiple Substrates and a Two-Site Model
Drug Metab. Dispos., July 1, 2001; 29(7): 1029 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Zalko, E. Perdu-Durand, L. Debrauwer, M.-P. Bec-Ferte, and J. Tulliez
Comparative Metabolism of Clenbuterol by Rat and Bovine Liver Microsomes and Slices
Drug Metab. Dispos., January 1, 1998; 26(1): 28 - 35.
[Abstract] [Full Text]

Home page
 Hum Exp ToxicolHome page
P. Hlavica, I. Golly, M. Lehnerer, and J. Schulze
Primary aromatic amines: their N-oxidative bioactivation
Human and Experimental Toxicology, August 1, 1997; 16(8): 441 - 448.
[Abstract] [PDF]

Home page
 ScienceHome page
X Jiang, G Khursigara, and R. Rubin
Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils
Science, November 4, 1994; 266(5186): 810 - 813.
[Abstract] [PDF]

Home page
 LupusHome page
L. M. Ayer, S. M. Edworthy, and M. J. Fritzler
Effect of Procainamide and Hydralazine on Poly (ADP-ribosylation) in Cell Lines
Lupus, June 1, 1993; 2(3): 167 - 172.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics.